News

Minocycline slows progress of Huntington's disease in mice

BMJ 2000; 321 doi: https://doi.org/10.1136/bmj.321.7253.70 (Published 08 July 2000) Cite this as: BMJ 2000;321:70
  1. Abi Berger
  1. BMJ

    The antibiotic minocycline seems to slow the progression of Huntington's disease in mice. Scientists at Brigham and Women's Hospital-Harvard Medical School in Boston have found that administering minocycline to mice with Huntington's disease resulted in a significant slowing of disease progression (Nature Medicine 2000;6:797-801).

    Dr Robert Friedlander, a neurosurgeon, and his team decided to try minocycline (an antibiotic commonly used to treat acne and rheumatoid arthritis) after research published last year showed that mice treated with it both before and after the induction of stroke seemed to sustain less brain damage than mice that were not treated.

    Minocycline is known to cross the blood-brain barrier, and it has been shown to inhibit the expression of the enzyme caspase-1 in brain damaged mice. Caspase-1 is involved in apoptosis (programmed cell death), which is an important mechanism in the pathogenesis of Huntington's disease. Dr Friedlander and his group showed last year that activated caspase-1 drives the progression of the disease in both humans and mice.

    When the researchers administered minocycline to mice with the disease, progression was slowed and the mice lived 14% longer. Dr Friedlander says that in humans with the disease this might be equivalent to surviving for one to five years longer.

    The researchers also observed that the disease could be slowed at an early stage, when there were few detectable symptoms. This implies that useful brain function, not just brain tissue, could be conserved. The team also found that caspase-1 expression was inhibited by 50% with minocycline treatment. The incidence of side effects with high doses of minocycline seemed to be greater in the mice with Huntington's disease than in the mice without the disease.

    In conditions like Huntington's disease, where the brain undergoes a continuing insult, many pathogenic pathways are triggered simultaneously. Caspase-1 activation is just one of these pathways, so any successful treatment will probably need to address multiple pathways simultaneously. This differs from the situation in which there is a single insult, such as in brain injury or stroke.

    “Minocycline might be just one of a combination of treatments that will eventually stop Huntington's disease, a bit like the cocktail of medications being used for HIV,” says Dr Friedlander.


    Embedded Image

    “Methods of analysis” (above) is part of an exhibit in the new £50m Wellcome wing of the Science Museum, opened last week by the Queen. It will form part of a section known as “Live Science,” in which scientists will use the wing as a base for carrying out research. Professor David Hopkinson of University College London, who is looking at the genetics of facial features, will analyse the faces of visitors to the museum.

    The wing also includes a 450 seat IMAX cinema and a suite of six specially created exhibitions covering key scientific topics, including genetics, digital technology, biomedicine and artificial intelligence. It aims to break down barriers between the public and the world of science by asking visitors for their opinions and feelings. Through art installations devised by some of the world's leading artists it also tries to make visitors look at science from a new perspective.

    View Abstract

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe